SPOTLIGHT -
A. Gordon Smith, MD, FAAN, discusses how to assess for treatment success and why the patient perspective is so important in deciding whether to change therapies.
FDA Clears Exploration Trial for Higher Dose of CTI-1601 for Friedreich Ataxia
Episode 95: Expanding Potential for Long-Term Treatment in SMA
SARA Scale Scores Strongly Predictive of Friedreich Ataxia Progression
Special Episode: SRP-9001 Approved As First Gene Therapy for Duchenne Muscular Dystrophy
Celebrating LGMD Awareness Day: Advances and Future Directions
Neuro News Roundup: LGMD Awareness Day – Expert Insight and Latest Literature